Cargando…
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases...
Autores principales: | Hsieh, Mao-Chih, Lu, Chang-Yun, Chang, Wei-Wen, Wu, Szu-Yuan, Hsiao, Ping-Kun, Liu, Tse-Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500057/ https://www.ncbi.nlm.nih.gov/pubmed/28658135 http://dx.doi.org/10.1097/MD.0000000000007306 |
Ejemplares similares
-
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis
por: Lin, En-Kwang, et al.
Publicado: (2016) -
Ten years’ disease-free survival of advanced epithelial ovarian cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A case report and literature review
por: Zhang, Jue, et al.
Publicado: (2020) -
Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination
por: Yu, Hsin-Hsien, et al.
Publicado: (2019) -
Anesthetic concerns during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: Ryu, Jung-Hee, et al.
Publicado: (2021) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019)